/
Infectious Disease
Meningioma
30
Pipeline Programs↗
35
Active Trials↗
16
Companies Involved↗
Meningioma is an emerging landscape with 30 programs across 16 companies. The most active players are Shanghai Runshi Pharmaceutical Technology Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 19
Phase 215
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
20 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 90% of 30 pipeline programs.
Analysis
Trial Status
73
clinical trials
Completed25 · 34%
Recruiting24 · 33%
Active, not recruiting8 · 11%
Unknown status6 · 8%
Terminated5 · 7%
Not yet recruiting3 · 4%
Other2 · 3%
Clinical Trials
Trial Activity
73 trials
Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)
Recruiting·—·Preclinical·NCT07150806·30 enrolled
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Recruiting·—·Phase 1·NCT07493447·30 enrolled
Abemaciclib in Newly Diagnosed Meningioma Patients
Recruiting·—·Phase 2·NCT05940493·72 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)